ImpactBridging European biotechs directly into Australia’s Clinical Trial Notification (CTN) scheme and the 43.5% R&D tax incentive without the friction of initial IND filings. AusNordia provides an authentic, clinically grounded interface that eliminates cross-continental operational drag, aligning foreign protocols with verified Australian trial sites, Academic Medical Centres (AMCs), and experienced Principal Investigators.
Driving Innovation. Accelerating Translation. Advancing Patient Care.
Bio-Runway
A clear path accelerating European and Nordic biomedical innovation into Australia’s clinical trial, hospital research, and advanced biomanufacturing ecosystem.
EUROPEAUSTRALIA
01 / The opportunity
Cross-border potential needs more than an idea.
02 / The Bio-Runway
One Runway.
Many Horizons.
Your Choice.
We help make the journey between where you want to be and how you’re going to get there: strategically aligned, scientifically grounded and ready for action.
Back to top 03 / What we do
Clarity for
the next move.
The six pathways that connect the Bio-Runway to Europe and Australia.
ImpactAustralia’s evolving privacy framework requires proactive oversight to satisfy strict EU standards. AusNordia acts as a cross-border compliance watchdog, bridging the data governance gap between domestic trial execution and the stringent expectations of the European Medicines Agency (EMA) and EU sponsors. We assure European General Data Protection Regulation (GDPR) data discipline, uncompromised GCP-compliant key-coded data governance, and robust health data security protocols—ensuring trial data generated across Australian sites withstands rigorous international regulatory audit.
ImpactTranslating 30+ years of bedside and laboratory leadership across multinational longitudinal studies into hospital-grade pre-analytical oversight. AusNordia follows rigorous site-level Standard Operating Procedures (SOPs), supervising complex biological sampling (e.g. specialised Peripheral Blood Mononuclear Cell - PBMC), de-identified sample chain of custody and validated cryogenic cold-chain logistics. Our focus is to safeguard human biospecimen integrity to satisfy EMA, TGA and ICH-GCP standards for biomarker discovery and secondary clinical endpoints.
ImpactPreventing costly data rejections and protocol redesigns when trials transition between hemispheres. AusNordia aligns early-phase Australian clinical trial designs, Human Research Ethics Committee (HREC) submissions, and investigator brochures with the strict regulatory mandates of the European Medicines Agency (EMA), the In Vitro Diagnostic Regulation (IVDR), and the Medical Device Regulation (MDR), ensuring all data generated in Australia is fully exportable to European registration dossiers.
ImpactConnecting European sponsors and independent Australian Contract Research Organisations (CROs) with high-performing regional clinical trial networks and emerging health precincts. By activating underutilised regional capacity, AusNordia accelerates recruitment milestones, expands patient demographic diversity, and bypasses the administrative delays typical of major metropolitan hospital networks.
ImpactAligning cross-border assets with specialised Australian biomanufacturing capabilities—including advanced therapy workflows, nucleic acid platforms, and formulation scale-up. AusNordia provides the operational and corporate architecture for high-level international alliances, acting as a compliant Australian industry partner to navigate university Research Business Office (RBO) due diligence e.g. Horizon Europe Pillar II (Cluster 1: Health) consortia and Medical Research Future Fund (MRFF) initiatives.
04 / Founder’s Lounge
Why AusNordia Was Established
Science knows no borders, but clinical translation requires structured pathways, cultural alignment, and active, local community engagement to succeed.
“AusNordia was established to be the trusted Bio-runway, the platform where complex international science meets local execution and institutional trust. We directly bridge critical gaps in cross-cultural alignment and rigorous data - & biospecimen integrity—embedding European GDPR standards, ICH-GCP trial governance, and uncompromising compliance into every cross-border pipeline.
Grounded in 30+ years of European hospital diagnostics, Tier-1 MedTech leadership, and clinical trial governance, I bring high-level expertise to support the growth of Australian life sciences. Building on this international foundation, backed by 4.5 years of direct engagement within Australia’s healthcare architecture and university networks, AusNordia eliminates cross-border friction to speed up clinical translation”
— Hanna K. Kanti-Paul, Founder & CEO
Read Hanna’s full bio05 / Advocacy & Engagement
Translational Advocacy & Institutional Engagement
Translational Infrastructure & Scientific Co-Creation
Scientific SponsorshipProduced in partnership with Prof. Derek Richard (Scientific Director, Cancer & Ageing Research Program - CARP at Queensland University of Technology - QUT).
OverviewHighlighting cutting-edge research infrastructure and scientific translation capability in Queensland.
Media ProductionHaZ2B Pty Ltd — Zoran Kanti-Paul
Cross-Sector Media & Parliamentary Engagement
CollaborationOrchestrated campaign uniting Queensland State Parliament representation (DETSI), The University of Queensland (UQ MND Research Group), and the MND and Me Foundation.
OverviewDemonstrating how non-traditional networks, executive diplomacy, and creative media drive major public health advocacy.
Media ProductionHaZ2B Pty Ltd — Zoran Kanti-Paul
Queensland, Australia
Begin a conversation with AusNordia.
AusNordia HaZ2B Pty Ltd t/a AusNordia
Hanna K. Kanti-Paul, MHML, BBMedSc
Founder & CEO